CAR-T cells for the treatment of relapsed/refractory multiple myeloma in 2022: efficacy and toxicity

Authors

KREJČÍ Martin ADAM Zdeněk KREJČÍ Marta POUR Luděk SANDECKÁ Viera ŠTORK Martin

Year of publication 2022
Type Article in Periodical
Magazine / Source Neoplasma
MU Faculty or unit

Faculty of Medicine

Citation
Web http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=7769&category_id=180&option=com_virtuemart
Doi http://dx.doi.org/10.4149/neo_2022_220504N477
Keywords relapsed/refractory multiple myeloma; CAR-T cells
Attached files
Description Chimeric antigen receptor (CAR)-T cells are a new treatment modality in various hematological malignancies, including relapsed/refractory multiple myeloma (RRMM). RRMM patients have a poor prognosis, and their treatment options are limited. Currently available data from clinical trials on CAR-T cell therapy have demonstrated efficacy and manageable toxicity in RRMM. The CAR-T cells in RRMM mostly focus on already known cellular targets, such as B-cell maturation antigen (BCMA). CAR-T cells focusing on other targets have been analyzed in various clinical trials as well. Cytokine release syndrome (CRS), specific neurotoxicity, and hematological toxicity are the main adverse events (AE); according to the clinical trials, they are mostly mild with a low incidence of grade 3 or higher toxicities. The autologous CAR-T cell therapy against BCMA (ide-cel and cilta-cel) shows the best efficacy with an overall response rate and a median progression-free survival in RRMM. Both ide-cel and cilta-cel have already been approved by the FDA. Currently, the main controversies in the routine use of CAR-T cells are high treatment costs and unknown long-term efficacy. In this review, we summarize the current overview of CAR-T cell therapies in RRMM in 2021 with various targets for CAR-T cells and their efficacy, safety, and possible limitations. Future prospective clinical trials are needed to clarify the optimal role of CAR-T cells in MM therapy.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info